AI-generated · cited to primary sources · not investment advice
P I Industries (523642) Nov 2025 Filing Analysis
Does management do what it says?
The recovery target is explicitly positioned for Q4 FY26, which is not covered by this Q3 FY26 presentation. Current 9MFY26 results still show AgChem exports down 20% year-on-year and domestic revenue down approximately 6% year-on-year, while management states that Q4 sequential growth is expected based on committed customer offtake. (1 not yet due across 1 tracked commitment)
“We also anticipate a recovery in our domestic and agchem exports, particularly in Q4, to offset the decline in revenue and profitability in the first half.”
Provide FY27 visibility and guidance in Q4 FY26 after assessing inventory restocking and normalisation.
“But yes, we will surely guide you sometime in the fourth quarter around what is our visibility for FY27.”
See the full cited Management analysis of P I Industries
How durable is the business?
The export order pipeline remained substantial despite the near-term revenue contraction. The disclosed CSM order book was approximately USD 1.25 billion in Q2 FY26, supporting medium-term visibility, but no comparable earlier value is provided in this document. (1 stable)
“We generally keep track on the overall order book position, which is around $1.25 billion as of now.”
See the full cited Business Model analysis of P I Industries
Where does growth come from?
The order book remains substantial at approximately USD 1.25 billion, but management has not provided a year-specific FY27 order-book view. Recovery is expected from Q4 FY26, while broader industry restocking is expected over the next 2-3 quarters. The absolute order book is positive, but near-term conversion visibility remains cautious. (1 steady, 1 accelerating across 2 signals)
“We generally keep track on the overall order book position, which is around $1.25 billion as of now... it is too early to guide you for FY27... we anticipate recovery from Q4FY26... we see recovery in the second half of calendar year 2026.”
See the full cited Future Growth analysis of P I Industries
What could break the thesis?
Competitive pressure was already intense in Q2 FY26: management specifically cited sharp price deflation from Chinese overcapacity and value erosion in generic products. The company responded with new molecules and differentiated products, but the Aug 2026 baseline still identified Chinese competition as a high risk. There is no evidence that the competitive threat had eased. (1 stable)
“This demand softness has been coupled with excess capacity in China, causing value erosion, particularly in the generic products.”
See the full cited Risk analysis of P I Industries
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.